What is 17-Alpha-Estradiol (males) and how does it affect longevity?

17-Alpha-Estradiol (males) is a pharmaceuticals-based intervention that research suggests may add 1.3 years to your lifespan compared to the average person. Naturally occurring weak estrogen with very low feminizing activity that extended median lifespan by +19% in male mice in the NIA ITP — one of the most sex-specific longevity findings ever documented. Zero effect in females across all doses and cohorts. Our analysis of the scientific literature gives this intervention an overall evidence rating of "Limited" (46%), combining peer-reviewed research (weighted at 85%) with expert consensus (15%). This rating reflects both the quality and quantity of available evidence — meaning early evidence is suggestive but limited by small studies, lack of human trials, or inconsistent findings.

Is 17-alpha-estradiol (males) scientifically proven to extend lifespan?

17-Alpha-Estradiol (males) has a scientific evidence score of 43% based on our analysis of peer-reviewed research. It's important to understand that no intervention has been "proven" to extend human lifespan in a definitive randomized controlled trial — such a study would require following thousands of people for decades. What we do have is a body of evidence from multiple research approaches: large observational cohort studies tracking health outcomes over 10-30+ years, randomized controlled trials measuring disease risk factors and biomarkers of aging, mechanistic studies explaining how the intervention affects cellular aging processes, and meta-analyses that combine results across multiple studies. Our scoring weights meta-analyses and large RCTs most heavily, followed by prospective cohort studies, then smaller trials and pre-clinical research. The lower science score reflects that much of the current evidence comes from preliminary studies, animal models, or small trials that need replication.

How many years can using 17-alpha-estradiol (males) add to my life?

17-Alpha-Estradiol (males) has an overall evidence score of 46% (rated "Limited"), placing it among the less-established pharmaceuticals interventions we evaluate. With a potential impact of 1.3 years, it offers a moderate estimated effect. Different interventions work through distinct biological mechanisms (metabolic pathways, inflammatory cascades, hormonal signaling, cellular repair), which means they often complement rather than compete with each other. Visit our Rankings page to compare all pharmaceuticals interventions side by side.

What are the risks or side effects of 17-alpha-estradiol (males)?

Pharmaceutical interventions carry meaningful risks including side effects, drug interactions, and potential long-term effects that aren't fully characterized for off-label longevity use. These should only be considered under medical supervision, ideally with a physician experienced in longevity medicine. Regular blood work monitoring is essential.

Can I combine 17-alpha-estradiol (males) with other longevity interventions?

Yes, and in fact most longevity researchers recommend combining multiple evidence-based interventions for the greatest overall effect. Pharmaceutical interventions should be approached cautiously when combining with supplements, as drug interactions are common. For example, metformin may reduce some exercise benefits; rapamycin affects immune function; and berberine interacts with many medications through CYP enzyme pathways. Always disclose all supplements and medications to your prescribing physician.

How long until I see results from using 17-alpha-estradiol (males)?

Pharmaceutical effects on biomarkers (blood glucose, inflammatory markers, mTOR activity) can appear within weeks. However, demonstrating actual lifespan extension in humans requires decades of data, which is why much of the evidence relies on surrogate endpoints and animal models. Monitor key biomarkers regularly to track your individual response. It's worth noting that the most important longevity benefits — reduced risk of chronic disease and increased healthspan — are largely invisible in day-to-day experience. You won't "feel" your cancer risk dropping or your telomeres lengthening. This is why tracking objective biomarkers (blood work, body composition, cardiovascular fitness tests) is valuable for maintaining motivation and confirming the intervention is working for you.

17-Alpha-Estradiol (males)

Estimated longevity benefit: +1.3 years. Evidence score: 46/100.

Overview

Naturally occurring weak estrogen with very low feminizing activity that extended median lifespan by +19% in male mice in the NIA ITP — one of the most sex-specific longevity findings ever documented. Zero effect in females across all doses and cohorts.

Evidence assessment

17-Alpha-estradiol (17α-E2) is a naturally occurring stereoisomer of the primary female sex hormone 17-beta-estradiol (17β-E2). The alpha and beta designations refer to the spatial orientation of the hydroxyl group at carbon-17. This small structural difference has profound biological consequences: 17α-E2 has approximately 0.2–2% of the feminizing potency of 17β-E2 at classical estrogen receptors (ERα and ERβ), yet it appears to engage non-classical metabolic and inflammatory pathways that, in males, produce striking longevity effects.

The ITP Finding: This is among the most surprising and reproducible results in the ITP's 20-year history: - Harrison et al. 2014 (first test): 17α-E2 extended median lifespan +19% in males at 14 ppm - Strong et al. 2016 (replication): The result held in an independent cohort at multiple doses - Maximum lifespan: +12% in males — even the longest-lived male mice benefited - Female mice at all doses: Zero effect — this complete sex specificity has held across every cohort tested - The effect was seen whether treatment started at 10 months or later in life

Why Males Only? The Mechanisms Are Still Being Investigated: The complete sex specificity of 17α-E2 is biologically fascinating and not fully explained. Current leading hypotheses: 1. Androgen interaction: 17α-E2 may interact differently with testosterone or downstream androgen pathways. Males have dramatically different baseline hormonal environments that may set up the longevity effect. 2. Non-classical ER signaling: 17α-E2 appears to activate GPER1 (a membrane-bound estrogen receptor) and ERβ in hypothalamic regions that control metabolic function. These pathways differ between sexes. 3. Fat redistribution: Male mice on 17α-E2 show reduced visceral adiposity. Visceral fat is a primary driver of age-related inflammation in males. 4. Reduced inflammation: Treated males show lower levels of pro-inflammatory cytokines (IL-6, TNF-α) and altered macrophage function — consistent with metabolic improvements. 5. Improved insulin sensitivity and glucose metabolism — measured directly in ITP cohorts showing 17α-E2 effects.

Important Context: - 17α-E2 is NOT the same as estrogen hormone therapy (which uses 17β-E2) - It is a research compound not FDA-approved for any indication - The mechanisms make it fundamentally different from HRT - The Jiang et al. 2025 review of 20 years of ITP data lists 17α-E2 as one of the most intriguing sex-specific findings in the entire program

The Broader ITP Pattern: 17α-E2 fits the dominant pattern in ITP data: 12 of 13 individual compounds that extended lifespan did so preferentially or exclusively in males. Rapamycin is the major exception. Whether this reflects fundamental biology of aging or artifacts of the mouse model remains a key research question.

Implementation protocol

Critical Warning: - 17-Alpha-estradiol is a research compound with NO FDA-approved indication - It is NOT approved for human use in any country for longevity purposes - It is fundamentally different from estrogen hormone replacement therapy (HRT) - Any interest in this compound should be discussed with a physician specializing in longevity medicine

Current Research Status: - Human trials are being planned/initiated based on the compelling ITP data - The Buck Institute, UT Health San Antonio (ITP's own center), and other longevity research programs are exploring translational studies - The compound can be obtained through compounding pharmacies in some jurisdictions but lacks dosing, safety, and efficacy data in humans

Why This Is Not a Standard Protocol: Unlike other ITP compounds (acarbose, captopril) that have decades of human use data from their approved indications, 17α-E2 has never been systematically studied in humans for any indication. Dosing, absorption, metabolism, and safety in humans are not established.

Key Scientific Contacts: - The UT Health San Antonio Barshop Institute (Strong lab) is the primary ITP site studying 17α-E2 - The Buck Institute for Research on Aging runs translational programs derived from ITP findings - ClinicalTrials.gov should be monitored for emerging human trials

For Clinicians Considering This: The sex specificity (males only) means that any human trial or off-label use should be in males. The mechanism research is being conducted at multiple institutions and is expected to produce human feasibility data within the next few years. This intervention is best categorized as "watch this space" with compelling preclinical evidence but no human protocol yet.

Scientific citations

Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males (Aging Cell · 2014)
Supports
Harrison DE, Strong R, Allison DB, et al.
First ITP test: 17α-estradiol extended median lifespan +19% in males, +12% maximum lifespan. Zero effect in females at any dose. Result replicated in independent cohort.
View paper
Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer (Aging Cell · 2016)
Supports
Strong R, Miller RA, Antebi A, et al.
ITP replication confirming 17α-estradiol's male-specific lifespan extension across multiple cohorts and doses. Mechanistic data shows reduced fat mass and improved glucose metabolism in treated males.
View paper
17α-Estradiol alleviates age-related metabolic and inflammatory dysfunctions in male mice (Aging Cell · 2017)
Supports
Stout MB, Steyn FJ, Jurczak MJ, et al.
Mechanistic study: 17α-E2 reduces visceral adiposity, liver lipid accumulation, and pro-inflammatory cytokines in male mice. Confirms metabolic and anti-inflammatory mechanisms underlying the ITP lifespan finding.
View paper
Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program (Journals of Gerontology Series A · 2025)
Questions
Jiang N, Xu Z, Zhao S, et al.
20-year review confirms 17α-estradiol's complete sex specificity is unexplained. No human safety, dosing, or efficacy data exists. The mechanism of male-only benefit remains a key open question.
View paper

Expert perspectives

David Sinclair, PhD Supports: The sex-specificity of 17-alpha-estradiol is one of the most striking patterns in aging biology. It points to fundamental biological differences in how males and females age that we don't fully understand.
Luigi Ferrucci, MD, PhD Questions: 17-alpha-estradiol has no approved indication, no human safety data, and an unexplained mechanism. It belongs in research programs, not in anyone's supplement stack.
Brian Kennedy, PhD Supports: 17-alpha-estradiol is one of the most fascinating ITP findings. A weak estrogen that extends male lifespan by 19% with zero effect in females — that complete sex specificity is biologically extraordinary and not yet explained.
Peter Attia, MD Supports: The metabolic and anti-inflammatory effects of 17-alpha-estradiol in male mice are compelling. The challenge is that this is a research compound with no human data whatsoever. Until we have human trials, this is more interesting science than actionable medicine.
Valter Longo, PhD Questions: There is no human evidence for 17-alpha-estradiol whatsoever. The preclinical data is interesting but we are far from recommending this to anyone.